Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors

NCT04226066 is registered in ClinicalTrials.gov with Tasly Tianjin Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT04226066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04226066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors
Lead sponsor
Tasly Tianjin Biopharmaceutical Co., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
November 20, 2019
Completion date
May 31, 2022
Enrollment
69 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid tumors